Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Bruker (BRKR)

Bruker adds Jack Phillips to board, expanding it to eleven directors effective January 1, 2026

Neutral Impact 2 of 5 leadership Written later

Bruker Corporation's board increased its size by one seat to eleven directors and appointed Jack J. Phillips to fill the new seat, effective January 1, 2026. Phillips, a former Accelerate Diagnostics and Roche Diagnostics North America executive, will serve until the 2027 annual meeting, and the company says his diagnostics experience will support its infectious disease and specialty diagnostics efforts.

Key points

  • Board expanded to eleven directors; Phillips assigned to Class III and will serve until the 2027 Annual Meeting of Stockholders.
  • Phillips was President and CEO of Accelerate Diagnostics from 2020 to 2025 and President and CEO of Roche Diagnostics North America from 2010 to 2020.
  • Phillips' director compensation will match that of other non-employee directors, as described in the April 11, 2025 proxy statement.
  • Bruker will file an amended Form 8-K later to disclose his committee assignments.

The filing

CompanyBruker (BRKR)
Form8-K, current report
Filed with the SECDec 9, 2025, 10:10 AM ET
Accession number0001193125-25-312106

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:17 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on December 09, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.